EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)ÄquivalenzstudieOpen Access · CC BY 4.0

12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study

Ondrej Viklicky, Ivan Zahradka, Jan Mares, Janka Slatinska, Alena Parikova, Vojtech Petr, Matej Roder, Katerina Jaklova, Klara Osickova, Libor Janousek, Petra Hruba

Transplant International · 2025

DOI: 10.3389/ti.2025.14312 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Transplant International, 2025. Verfasst von Ondrej Viklicky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Desensitization, Immunologic, Graft Rejection, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intravenous immunoglobulins (IVIG) are commonly used in peri-transplant desensitization, but evidence supporting their efficacy is limited. We conducted a prospective, randomized single-center, open-label, Phase IIIb non-inferiority clinical pilot trial to compare the efficacy of IVIG (administered at a dose of 3 × 0.5 g/kg) versus no IVIG, in conjunction with rabbit anti-thymocyte globulin (5–7 mg/kg) induction, in pre-sensitized patients with donor-specific antibodies who had negative pre-transplantation Flow- and CDC-crossmatches, between July 2020 and November 2022. The primary endpoint was the rate of efficacy failure, defined as biopsy-proven rejection within 12-month post-transplant. Secondary endpoints included the incidence of rejection at protocol biopsies, evaluated by histology and biopsy-based transcripts diagnostics. Of the screened patients, 53 (72.6%) were excluded due to crossmatch positivity. Ten patients were randomized to the IVIG+, and 7 to the IVIG-arm. The trial was prematurely terminated due to futility at interim analysis. In the IVIG-arm, 3 patients (43%) experienced the primary endpoint compared to none in the IVIG+ arm (p = 0.026). MMDx identified one molecular ABMR in the IVIG+ and 2 in the IVIG-arm in 12-month protocol biopsies. There was one graft loss in the IVIG-arm. The results of this pilot study, although not definitive, do not support the use of IVIG-sparing regimens in HLA-incompatible kidney transplantation (NCT04302805). This study is registered on ClinicalTrials.gov under the identifier NCT04302805.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antilymphocyte SerumDesensitization, ImmunologicGraft RejectionImmunoglobulins, IntravenousKidney TransplantationAdultAnimalsFemaleHumansMaleMiddle AgedPilot ProjectsProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

HLA-incompatible transplantationIVIGdesensitizationinductionkidney transplantation

Substanzen

Antilymphocyte SerumImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
  • Transplantation Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czechia.
  • Department of Data Science, Institute for Clinical and Experimental Medicine, Prague, Czechia.
  • Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia.
  • Department of Transplantation Surgery, Institute for Clinical and Experimental Medicine, Prague, Czechia.

Zitieren

APA

Viklicky, O., Zahradka, I., Mares, J., Slatinska, J., Parikova, A., Petr, V., Roder, M., Jaklova, K., Osickova, K., Janousek, L., & Hruba, P. (2025). 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study. Transplant International. https://doi.org/10.3389/ti.2025.14312

Vancouver

Viklicky O, Zahradka I, Mares J, Slatinska J, Parikova A, Petr V, et al. 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study. Transplant International. 2025. doi:10.3389/ti.2025.14312

BibTeX
@article{Viklicky2025,
  author = {Viklicky, Ondrej and Zahradka, Ivan and Mares, Jan and Slatinska, Janka and Parikova, Alena and Petr, Vojtech and Roder, Matej and Jaklova, Katerina and Osickova, Klara and Janousek, Libor and Hruba, Petra},
  title = {12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study},
  journal = {Transplant International},
  year = {2025},
  doi = {10.3389/ti.2025.14312}
}
Kostenlos starten →